drugset / Trial / NCT04002284
Anlotinib in Metastatic HER2 Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is to discover if the anlotinib can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.
Timeline
- Start
- 2018-07-12
- Primary completion
- 2020-01-10
- Completion
- 2020-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |